Barrett's esophagus

From Wikipedia, the free encyclopedia
  (Redirected from Barrett's esophagitis)
Jump to: navigation, search
Barrett's esophagus
Classification and external resources
Barretts esophagus.jpg
Endoscopic image of Barrett's esophagus, which is the area of red mucosa projecting like a tongue. Biopsies showed intestinal metaplasia.
ICD-10 K22.7
ICD-9 530.85
OMIM 109350
DiseasesDB 1246
MedlinePlus 001143
eMedicine radio/73
NCI Barrett's esophagus
Patient UK Barrett's esophagus
MeSH D001471

Barrett's esophagus (British English: Barrett's oesophagus), sometimes called Barrett syndrome, Barrett esophagus, or columnar epithelium lined lower oesophagus (CELLO), refers to an abnormal change (metaplasia) in the cells of the lower portion of the esophagus. It is characterized by the replacement of the normal stratified squamous epithelium lining of the esophagus by simple columnar epithelium with goblet cells (which are usually found lower in the gastrointestinal tract). The medical significance of Barrett's esophagus is its strong association (about 0.5% per patient-year) with esophageal adenocarcinoma, a very often deadly cancer,[1][2] because of which it is considered to be a premalignant condition.

The main cause of Barrett's esophagus is thought to be an adaptation to chronic acid exposure from reflux esophagitis.[3] The incidence of esophageal adenocarcinoma has increased substantially in the Western world in recent years.[1] The condition is found in 5–15% of patients who seek medical care for heartburn (gastroesophageal reflux disease), although a large subgroup of patients with Barrett's esophagus do not have symptoms.[1] Diagnosis requires endoscopy (more specifically, esophagogastroduodenoscopy, a procedure in which a fibreoptic cable is inserted through the mouth to examine the esophagus, stomach, and duodenum) and biopsy. The cells of Barrett's esophagus, after biopsy, are classified into four general categories: nondysplastic, low-grade dysplasia, high-grade dysplasia, and frank carcinoma. High-grade dysplasia and early stages of adenocarcinoma can be treated by endoscopic resection and new endoscopic therapies such as radiofrequency ablation, whereas advanced stages (submucosal) are generally advised to undergo surgical treatment. Nondysplastic and low-grade patients are generally advised to undergo annual observation with endoscopy, with radiofrequency ablation as a therapeutic option. In high-grade dysplasia, the risk of developing cancer might be at 10% per patient-year or greater.[1]

The condition is named after the Australian-born British thoracic surgeon Norman Barrett (1903–1979), who described it in 1950.[4]

Signs and symptoms[edit]

The change from normal to premalignant cells that indicate Barrett's esophagus does not cause any particular symptoms. Barrett's esophagus, however, is associated with these symptoms:

  • frequent and longstanding heartburn
  • trouble swallowing (dysphagia)
  • vomiting blood (hematemesis)
  • pain under the sternum where the esophagus meets the stomach
  • unintentional weight loss because eating is painful

The risk of developing Barrett's esophagus is increased by central obesity (vs. peripheral obesity).[5] The exact mechanism is unclear. The difference in distribution of fat among men (more central) and women (more peripheral) may explain the increased risk in males.[6]

Mechanism[edit]

Micrograph of Barrett's esophagus, Alcian blue stain

Barrett's esophagus occurs due to chronic inflammation. The principal cause of the chronic inflammation is gastroesophageal reflux disease, GERD (UK: GORD). In this disease, acidic stomach, bile, and small intestine and pancreatic contents cause damage to the cells of the lower esophagus. Recently, bile acids were shown to be able to induce intestinal differentiation, in gastroesophageal junction cells, through inhibition of the epidermal growth factor receptor (EGFR) and the protein kinase enzyme Akt.[7] This results in the eventual up-regulation of the p50 subunit of protein complex NF-κB (NFKB1), and ultimately activation of the homeobox gene CDX2, which is responsible for the expression of intestinal enzymes such as guanylate cyclase 2C.[8] This mechanism also explains the selection of HER2/neu (also called ERBB2) and the overexpressing (lineage-addicted) cancer cells during the process of carcinogenesis, and the efficacy of targeted therapy against the Her-2 receptor with trastuzumab (Herceptin) in the treatment of adenocarcinomas at the gastroesophageal junction.

Researchers are unable to predict which heartburn sufferers will develop Barrett's esophagus. While no relationship exists between the severity of heartburn and the development of Barrett's esophagus, a relationship does exist between chronic heartburn and the development of Barretts esophagus. Sometimes, people with Barrett's esophagus have no heartburn symptoms at all. In rare cases, damage to the esophagus may be caused by swallowing a corrosive substance such as lye.

Diagnosis[edit]

Micrograph of Barrett's esophagus (left of image) and normal stratified squamous epithelium (right of image), Alcian blue stain
High-magnification micrograph of Barrett's esophagus showing the characteristic goblet cells, Alcian blue stain

Both macroscopic (from endoscopy) and microscopic positive findings are required to make a diagnosis. Barrett's esophagus is marked by the presence of columnar epithelia in the lower esophagus, replacing the normal squamous cell epithelium—an example of metaplasia. The secretory columnar epithelium may be more able to withstand the erosive action of the gastric secretions; however, this metaplasia confers an increased risk of adenocarcinoma.[9]

Intestinal metaplasia[edit]

The presence of goblet cells, called intestinal metaplasia, is necessary to make a diagnosis of Barrett's esophagus. This frequently occurs in the presence of other metaplastic columnar cells, but only the presence of goblet cells is diagnostic. The metaplasia is grossly visible through a gastroscope, but biopsy specimens must be examined under a microscope to determine whether cells are gastric or colonic in nature. Colonic metaplasia is usually identified by finding goblet cells in the epithelium and is necessary for the true diagnosis.

Many histologic mimics of Barrett's esophagus are known (i.e. goblet cells occurring in the transitional epithelium of normal esophageal submucosal gland ducts, "pseudogoblet cells" in which abundant foveolar (gastric) type mucin simulates the acid mucin true goblet cells). Assessment of relationship to submucosal glands and transitional-type epithelium with examination of multiple levels through the tissue may allow the pathologist to reliably distinguish between goblet cells of submucosal gland ducts and true Barrett's esophagus (specialized columnar metaplasia). Use of the histochemical stain Alcian blue pH 2.5 is also frequently used to distinguish true intestinal-type mucins from their histologic mimics. Recently, immunohistochemical analysis with antibodies to CDX-2 (specific for mid and hindgut intestinal derivation) has also been used to identify true intestinal-type metaplastic cells. The protein AGR2 is elevated in Barrett's esophagus,[10] and can be used as a biomarker for distinguishing Barrett epithelium from normal esophageal epithelium.[11]

Epithelial dyplasia[edit]

After the initial diagnosis of Barrett's esophagus is rendered, affected persons undergo annual surveillance to detect changes that indicate higher risk to progression to cancer: development of epithelial dysplasia (or "intraepithelial neoplasia").[12] Considerable variability is seen in assessment for dysplasia among pathologists. Recently, gastroenterology and GI pathology societies have recommended that any diagnosis of high-grade dysplasia in Barrett be confirmed by at least two fellowship-trained GI pathologists prior to definitive treatment for patients.[13] For more accuracy and reproductibility, it is also recommended to follow international classification system as the "Vienna classification" of gastrointestinal epithelial neoplasia (2000).[14]

Management[edit]

Many patients with Barrett's esophagus do not have dysplasia. Medical societies recommend that if a patient has Barrett's esophagus, and if the past two endoscopy and biopsy examinations have confirmed the absence of dysplasia, then the patient should not have another endoscopy within three years.[15][16][17]

Many professional medical societies propose endoscopic screening of patients with GERD and endoscopic surveillance of patients with Barrett's esophagus, although little direct evidence supports this practice, which is common in many developed countries.[1] Treatment options for high-grade dysplasia include surgical removal of the esophagus (esophagectomy) or endoscopic treatments such as endoscopic mucosal resection or ablation (destruction).[1]

The risk of malignancy is highest in the U.S. in Caucasian men more than 50 years of age with more than five years of symptoms. Current recommendations include routine endoscopy and biopsy (looking for dysplastic changes). Although in the past physicians have taken a watchful waiting approach, newly published research supports consideration of intervention for Barrett's esophagus. Balloon-based radiofrequency ablation, invented by Ganz, Stern, and Zelickson in 1999, is a new treatment modality for the treatment of Barrett's esophagus and dysplasia, and has been the subject of numerous published clinical trials.[18][19][20][21] The findings demonstrate radiofrequency ablation has an efficacy of 90% or greater with respect to complete clearance of Barrett's esophagus and dysplasia with durability up to five years and a favorable safety profile.[18][19][20][21]

Proton pump inhibitor drugs have not been proven to prevent esophageal cancer. Laser treatment is used in severe dysplasia, while overt malignancy may require surgery, radiation therapy, or systemic chemotherapy. Additionally, a recent five-year random-controlled trial has shown that photodynamic therapy using photofrin is statistically more effective in eliminating dysplastic growth areas than sole use of a proton pump inhibitor.[22] There is presently no reliable way to determine which patients with Barrett esophagus will go on to develop esophageal cancer, although a recent study found the detection of three different genetic abnormalities was associated with as much as a 79% chance of developing cancer in six years.[23]

Endoscopic mucosal resection has also been evaluated as a management technique.[24] Additionally an operation known as a Nissen fundoplication can reduce the reflux of acid from the stomach into the esophagus.[25]

In a variety of studies, nonsteroidal anti-inflammatory drugs (NSAIDS), like aspirin, have shown evidence of preventing esophageal cancer in Barrett's esophagus patients.[26][27] However, none of these studies have been randomized, placebo-controlled trials, which are considered the gold standard for evaluating a medical intervention. In addition, the best dose of NSAIDs for cancer prevention is not yet known.

Prognosis[edit]

Barrett's esophagus is a premalignant condition. Its malignant sequela, oesophagogastric junctional adenocarcinoma, has a mortality rate of over 85%.[28] The risk of developing esophageal adenocarcinoma in people who have Barrett's esophagus has been estimated to be 6–7 per 1000 person-years,[29][30] however a cohort study of 11,028 patients from Denmark published in 2011 showed an incidence of only 1.2 per 1000 person-years (5.1 per 1000 person-years in patients with dysplasia, 1.0 per 1000 person-years in patients without dysplasia).[31] Most patients with esophageal carcinoma survive less than 1 year.[32]

Epidemiology[edit]

The incidence in the United States among Caucasian men is eight times the rate among Caucasian women and five times greater than African American men. Overall, the male to female ratio of Barrett's esophagus is 10:1.[33] Several studies have estimated the prevalence of Barrett's esophagus in the general population to be 1.3% to 1.6% in two European populations (Italian[34] and Swedish[35]), and 3.6% in a Korean population.[36]

History[edit]

Barrett first described the columnar metaplasia in 1950.[4] An association with gastroesophageal reflux was made in 1953.[37] An association with adenocarcinoma was made in 1975.[38]

References[edit]

  1. ^ a b c d e f Shaheen NJ, Richter JE (March 2009). "Barrett oesophagus". Lancet 373 (9666): 850–61. doi:10.1016/S0140-6736(09)60487-6. PMID 19269522. 
  2. ^ Koppert L, Wijnhoven B, van Dekken H, Tilanus H, Dinjens W (2005). "The molecular biology of esophageal adenocarcinoma". J Surg Oncol 92 (3): 169–90. doi:10.1002/jso.20359. PMID 16299787. 
  3. ^ Stein H, Siewert J (1993). "Barrett's esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management". Dysphagia 8 (3): 276–88. doi:10.1007/BF01354551. PMID 8359051. 
  4. ^ a b BARRETT NR (October 1950). "Chronic peptic ulcer of the oesophagus and 'oesophagitis'". Br J Surg 38 (150): 175–82. doi:10.1002/bjs.18003815005. PMID 14791960. 
  5. ^ Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL (August 2007). "Central adiposity and risk of Barrett esophagus". Gastroenterology 133 (2): 403–11. doi:10.1053/j.gastro.2007.05.026. PMID 17681161. 
  6. ^ Reid BJ, Li X, Galipeau PC, Vaughan TL (February 2010). "Barrett oesophagus and oesophageal adenocarcinoma: time for a new synthesis". Nature Reviews Cancer 10 (2): 87–101. doi:10.1038/nrc2773. PMC 2879265. PMID 20094044. 
  7. ^ Gong L, Debruyne PR, Witek M, Nielsen K, Snook A, Lin JE, Bombonati A, Palazzo J, Schulz S, Waldman SA (2009). "Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis". Clin Transl Sci. 2 (4): 286–93. doi:10.1111/j.1752-8062.2009.00131.x. PMID 20443907. 
  8. ^ Debruyne PR, Witek M, Gong L, Birbe R, Chervoneva I, Jin T, Domon-Cell C, Palazzo JP, Freund JN, Li P, Pitari GM, Schulz S, Waldman SA (April 2006). "Bile acids induce ectopic expression of intestinal guanylyl cyclase C through nuclear factor-kappaB and Cdx2 in human esophageal cells". Gastroenterology 130 (4): 1191–206. doi:10.1053/j.gastro.2005.12.032. PMID 16618413. 
  9. ^ Fléjou J (2005). "Barrett's oesophagus: from metaplasia to dysplasia and cancer". Gut. 54 Suppl 1: i6–12. doi:10.1136/gut.2004.041525. PMC 1867794. PMID 15711008. 
  10. ^ Elizabeth Pohler, Ashley L. Craig, James Cotton, Laura Lawrie, John F. Dillon, Pete Ross, Neil Kernohan and Ted R. Hupp (2004). "The Barrett’s Antigen Anterior Gradient-2 Silences the p53 Transcriptional Response to DNA Damage". Molecular and Cellular Proteomics 3 (6): 534–547. doi:10.1074/mcp.M300089-MCP200. PMID 14967811. 
  11. ^ Murray E, McKenna EO, Burch LR, Dillon J, Langridge-Smith P, Kolch W, Pitt A, Hupp TR (2007). "Microarray-formatted clinical biomarker assay development using peptide aptamers to anterior gradient-2". Biochemistry 46 (48): 13742–51. doi:10.1021/bi7008739. PMID 17994709. 
  12. ^ Odze, R. D. (2006). "Diagnosis and grading of dysplasia in Barrett's oesophagus". Journal of Clinical Pathology 59 (10): 1029–38. doi:10.1136/jcp.2005.035337. PMC 1861756. PMID 17021130.  edit
  13. ^ Fléjou, J. F. (2005). "Barrett's oesophagus: From metaplasia to dysplasia and cancer". Gut. 54 Suppl 1: i6–12. doi:10.1136/gut.2004.041525. PMC 1867794. PMID 15711008.  edit
  14. ^ Schlemper, R. J.; Riddell, R. H.; Kato, Y; Borchard, F; Cooper, H. S.; Dawsey, S. M.; Dixon, M. F.; Fenoglio-Preiser, C. M.; Fléjou, J. F.; Geboes, K; Hattori, T; Hirota, T; Itabashi, M; Iwafuchi, M; Iwashita, A; Kim, Y. I.; Kirchner, T; Klimpfinger, M; Koike, M; Lauwers, G. Y.; Lewin, K. J.; Oberhuber, G; Offner, F; Price, A. B.; Rubio, C. A.; Shimizu, M; Shimoda, T; Sipponen, P; Solcia, E et al. (2000). "The Vienna classification of gastrointestinal epithelial neoplasia". Gut 47 (2): 251–5. doi:10.1136/gut.47.2.251. PMC 1728018. PMID 10896917.  edit
  15. ^ American Gastroenterological Association, "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation (American Gastroenterological Association), retrieved August 17, 2012 
  16. ^ American Gastroenterological Association; Spechler, S. J.; Sharma, P.; Souza, R. F.; Inadomi, J. M.; Shaheen, N. J. (2011). "American Gastroenterological Association Medical Position Statement on the Management of Barrett's Esophagus". Gastroenterology 140 (3): 1084–1091. doi:10.1053/j.gastro.2011.01.030. PMID 21376940.  edit
  17. ^ Wang, K. K.; Sampliner, R. E.; Practice Parameters Committee of the American College of Gastroenterology (2008). "Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus". The American Journal of Gastroenterology 103 (3): 788–797. doi:10.1111/j.1572-0241.2008.01835.x. PMID 18341497.  edit
  18. ^ a b Fleischer DE, Overholt, BF, Sharma VK, et al. (2010). "Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial". Endoscopy 42 (10): 781–9. doi:10.1055/s-0030-1255779. PMID 20857372. 
  19. ^ a b Shaheen NJ, Sharma, P, Overholt, BF, et al. (2009). "Radiofrequency Ablation in Barrett's Esophagus with Dysplasia". New England Journal of Medicine 360 (22): 2277–88. doi:10.1056/NEJMoa0808145. PMID 19474425. 
  20. ^ a b Shaheen NJ, Overholt, BF, Sampliner, RE et al. (2011). "Durability of Ablation in Barrett's Esophagus with Dysplasia". Gastroenterology 141 (2): 460–8. doi:10.1053/j.gastro.2011.04.061. PMC 3152658. PMID 21679712. 
  21. ^ a b van Vilsteren FG, Pouw RE, Seewald, S et al. (June 2011). "Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial". Gut 60 (6): 765–73. doi:10.1136/gut.2010.229310. PMID 21209124. 
  22. ^ Overholt BF, Wang KK, Burdick JS, et al. (2007). "Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett high-grade dysplasia.". Gastrointestinal endoscopy 66 (3): 460–8. doi:10.1016/j.gie.2006.12.037. PMID 17643436. 
  23. ^ Galipeau P, Li X, Blount PL, Maley CC, Sanchez CA Odze RD, Ayub K, Rabinovitch PS, Vaughan TV, Reid BJ (2007). "NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma". PLoS Medicine 4 (2): e67. doi:10.1371/journal.pmed.0040067. PMC 1808095. PMID 17326708. 
  24. ^ Reshamwala P, Darwin P (2006). "Endoscopic management of early gastric cancer". Current Opinion in Gastroenterology 22 (5): 541–5. doi:10.1097/01.mog.0000239870.04457.80. PMID 16891887. 
  25. ^ Abbas A, Deschamps C, Cassivi SD, et al. (2004). "The role of laparoscopic fundoplication in Barrett’s esophagus". Annals of Thoracic Surgery 77 (2): 393–396. doi:10.1016/S0003-4975(03)01352-3. PMID 14759403. 
  26. ^ Corley DA, Kerlikowske K, Verma R, Buffler P (2003). "Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis.". Gastroenterology 124 (1): 47–56. doi:10.1053/gast.2003.50008. PMID 12512029. 
  27. ^ Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez, CA, Rabinovitch PS, Reid BJ (2005). "Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study". Lancet Oncol 6 (12): 945–52. doi:10.1016/S1470-2045(05)70431-9. PMID 16321762. 
  28. ^ Holmes RS, Vaughan TL (January 2007). "Epidemiology and pathogenesis of esophageal cancer". Semin Radiat Oncol 17 (1): 2–9. doi:10.1016/j.semradonc.2006.09.003. PMID 17185192. 
  29. ^ Thomas T, Abrams KR, De Caestecker JS, Robinson RJ (December 2007). "Meta analysis: Cancer risk in Barrett's oesophagus". Aliment. Pharmacol. Ther. 26 (11–12): 1465–77. doi:10.1111/j.1365-2036.2007.03528.x. PMID 17900269. 
  30. ^ Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L (August 2008). "The incidence of esophageal cancer and high-grade dysplasia in Barrett esophagus: a systematic review and meta-analysis". Am. J. Epidemiol. 168 (3): 237––49. doi:10.1093/aje/kwn121. PMID 18550563. 
  31. ^ Hvid-Jensen F, et al. (2011). "Incidence of adenocarcinoma among patients with Barrett's esophagus". N Engl J Med 365: 1375–383. doi:10.1056/NEJMoa1103042. 
  32. ^ Polednak AP (May 2003). "Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas". Int. J. Cancer 105 (1): 98–100. doi:10.1002/ijc.11029. PMID 12672037. 
  33. ^ Zajac, P; Holbrook, A; Super, ME; Vogt, M (March–April 2013). "An overview: Current clinical guidelines for the evaluation, diagnosis, treatment, and management of dyspepsia". Osteopathic Family Physician 5 (2): 79–85. doi:10.1016/j.osfp.2012.10.005. 
  34. ^ Zagari RM, Fuccio L, Wallander MA, et al. (October 2008). "Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study". Gut 57 (10): 1354–9. doi:10.1136/gut.2007.145177. PMID 18424568. 
  35. ^ Ronkainen J, Aro P, Storskrubb T, et al. (December 2005). "Prevalence of Barrett esophagus in the general population: an endoscopic study". Gastroenterology 129 (6): 1825–31. doi:10.1053/j.gastro.2005.08.053. PMID 16344051. 
  36. ^ Kim JY, Kim YS, Jung MK, et al. (April 2005). "Prevalence of Barrett's esophagus in Korea". J. Gastroenterol. Hepatol. 20 (4): 633–6. doi:10.1111/j.1440-1746.2005.03749.x. PMID 15836715. 
  37. ^ ALLISON PR, JOHNSTONE AS (June 1953). "The oesophagus lined with gastric mucous membrane". Thorax 8 (2): 87–101. doi:10.1136/thx.8.2.87. PMC 1019247. PMID 13077502. 
  38. ^ Naef AP, Savary M, Ozzello L (November 1975). "Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett esophagus with 12 adenocarcinomas". J. Thorac. Cardiovasc. Surg. 70 (5): 826–35. PMID 1186274. 

External links[edit]